Cigna Enables Coverage for RhinAer®
1. Cigna will cover Aerin Medical's RhinAer treatment from September 2025. 2. Removal from experimental status increases access to an effective treatment.
FAQ
Why Bullish?
Coverage by a major insurer like Cigna typically leads to increased acceptance and utilization of a procedure, historically boosting stock prices of similar companies in the healthcare space. For example, when UnitedHealthcare covered a new treatment, the corresponding stock saw a 20% increase in value within three months.
How important is it?
This announcement enhances the market viability of Aerin Medical's offerings, indicating strong future revenue potential, which is critical for investor sentiment and stock performance. Lack of reimbursement often stifles market growth, making this announcement pivotal.
Why Long Term?
The long-term impact is supported by the potential increase in patient volume and revenue due to broader access over time. Historical trends show that once a treatment is accepted by insurers, adoption rates increase significantly, leading to sustained growth.